Investigating the HER3-PHF8 signaling pathway in triple-negative breast cancer
HER3-PHF8 signaling axis in triple-negative breast cancer progression
This study is looking at how two proteins, HER3 and PHF8, work together in triple-negative breast cancer to help us find better treatments for patients facing this tough type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lsu Health Sciences Center NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project ID | NIH-10992121 on NIH RePORTER |
What this research studies
This research focuses on understanding the HER3-PHF8 signaling axis in triple-negative breast cancer (TNBC), a subtype of breast cancer known for its aggressive nature and poor prognosis. The study aims to explore the role of HER3, a protein that is often overexpressed in TNBC, and its relationship with PHF8, an epigenetic modifier. By analyzing clinical samples and cell lines, researchers will investigate how these proteins contribute to tumor progression and resistance to existing therapies. The goal is to identify new molecular targets that could lead to more effective treatments for patients suffering from this challenging cancer type.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer, particularly those who have not responded well to current treatments.
Not a fit: Patients with other subtypes of breast cancer or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of novel therapies that improve outcomes for patients with triple-negative breast cancer.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in other cancer types, suggesting potential for success in this novel approach.
Where this research is happening
New Orleans, United States
- Lsu Health Sciences Center — New Orleans, United States (Active)
Researchers
- Principal investigator: Liu, Bolin — Lsu Health Sciences Center
- Study coordinator: Liu, Bolin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.